Stocks
Funds
Screener
Sectors
Watchlists

Latest Aisling Capital Management LP Stock Portfolio

Aisling Capital Management LP Performance:
2024 Q3: -0.9%YTD: -29.77%2023: 117.62%

Performance for 2024 Q3 is -0.9%, and YTD is -29.77%, and 2023 is 117.62%.

About Aisling Capital Management LP and 13F Hedge Fund Stock Holdings

In it's latest 13F Holdings report, Aisling Capital Management LP reported an equity portfolio of $261.1 Millions as of 30 Sep, 2024.

The top stock holdings of Aisling Capital Management LP are BBIO, VRNA, SNDX. The fund has invested 59.2% of it's portfolio in BRIDGEBIO PHARMA INC. (BBIO) and 12.3% of portfolio in VERONA PHARMA PLC (VRNA).

Aisling Capital Management LP opened new stock positions in BICARA THERAPEUTICS INC. (BCAX).

Aisling Capital Management LP Annual Return Estimates Vs S&P 500

Our best estimate is that Aisling Capital Management LP made a return of -0.9% in the last quarter. In trailing 12 months, it's portfolio return was -2.64%.

New Buys

Ticker$ Bought
bicara therapeutics inc. (bcax)14,490,400

New stocks bought by Aisling Capital Management LP

Additions

No additions were made to existing positions by Aisling Capital Management LP

Reductions

None of the existing positions were reduced by Aisling Capital Management LP

Sold off

None of the stocks were completely sold off by Aisling Capital Management LP

Sector Distribution

Aisling Capital Management LP has about 92.6% of it's holdings in Healthcare sector.

Sector%
Healthcare92.6
Others7.4

Market Cap. Distribution

Aisling Capital Management LP has about 0% of it's portfolio invested in the large-cap and mega-cap stocks.

Category%
MID-CAP71.5
SMALL-CAP13.3
UNALLOCATED7.4
MICRO-CAP6.9

Stocks belong to which Index?

About 77% of the stocks held by Aisling Capital Management LP either belong to S&P 500 or RUSSELL 2000 index.

Index%
RUSSELL 200077
Others23
Top 5 Winners (%)%
BMEA
biomea fusion inc (bmea)
124.4 %
GLUE
monte rosa therapeutics inc (glue)
41.7 %
RPHM
reneo pharmaceuticals inc (rphm)
12.6 %
ACRS
aclaris therapeutics inc (acrs)
4.5 %
BBIO
bridgebio pharma inc. (bbio)
0.5 %
Top 5 Winners ($)$
BMEA
biomea fusion inc (bmea)
4.5 M
GLUE
monte rosa therapeutics inc (glue)
2.3 M
BBIO
bridgebio pharma inc. (bbio)
0.8 M
RPHM
reneo pharmaceuticals inc (rphm)
0.2 M
ACRS
aclaris therapeutics inc (acrs)
0.0 M
Top 5 Losers (%)%
ELEV
elevation oncology inc (elev)
-77.8 %
VIRX
viracta therapeutics inc (virx)
-57.7 %
MRKR
marker therapeutics, inc. (mrkr)
-48.1 %
NUVB
nuvation bio inc. (nuvb)
-21.6 %
SNDX
syndax pharmaceuticals, inc. (sndx)
-6.2 %
Top 5 Losers ($)$
ELEV
elevation oncology inc (elev)
-6.0 M
NUVB
nuvation bio inc. (nuvb)
-1.6 M
SNDX
syndax pharmaceuticals, inc. (sndx)
-1.3 M
MRKR
marker therapeutics, inc. (mrkr)
-0.8 M
VIRX
viracta therapeutics inc (virx)
-0.1 M

Aisling Capital Management LP Holdings Map

This heatmap illustrates the top 50 positions within the fund's portfolio.

Current Stock Holdings of Aisling Capital Management LP

Aisling Capital Management LP has 16 stocks in it's portfolio. About 97.3% of the portfolio is in top 10 stocks. ELEV proved to be the most loss making stock for the portfolio. BMEA was the most profitable stock for Aisling Capital Management LP last quarter.

Last Reported on: 13 Nov, 2024
TickerNamesorted ascending% PortfolioShares Held$ ValueType% ChangeOptions